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ER attendance, costs were calculated multiplying resource use by corresponding unit 
costs. Regarding hospitalization, length of stay was multiplied by daily cost obtained 
through hospitals accountancy. Both costs were summed and descriptive statistics 
were calculated. Productivity loss cost within ER admission and hospitalization was 
calculated for employed patients using the Human Capital Approach. Results: 238 
patients were enrolled and 105 (44%) were hospitalized. These patients had a median 
length of stay of 5.4 days and were most commonly hospitalized at the Internal 
Medicine department (n= 80; 76%). Nine patients (8.6%) died during hospitalization. 
Hospitalized patients had the following average (range) costs: pre-hospital care and 
transport € 34 (€ 0-€ 92); emergency room € 218 (€ 58-€ 1,348); hospitalization € 2,880 
(€ 140-€ 26,486); productivity loss costs due to ER and hospitalization € 31 (€ 0-€ 1,579). 
Thus, mean total cost per hypoglycemic event leading to hospitalization was € 3,163 
(€ 230-€ 26,818). ConClusions: We conclude that severe hypoglycemia represent a 
substantial cost to Society and to the public hospitals of the National Health System 
in particular for those cases requiring hospitalization.
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objeCtives: Hypoglycemia, which if left untreated, can be severe and result in sei-
zures, unconsciousness, and coma, during which another person’s help is required to 
administer a rescue dose of glucagon. Injectable glucagon kits are difficult to use and 
require training to administer. This study aimed to quantify the economic impact of 
using glucagon kits on resource use and costs, and identify evidentiary gaps requiring 
future research. Methods: A conceptual model was developed illustrating the series 
of events resulting from a SHE: successful administration of glucagon, ambulance 
calls, transport to the ED, inpatient admission, and outpatient follow-up. A literature 
search was conducted to assess service use and costs associated with severe hypo-
glycemia events (SHE). English language articles were reviewed in PubMed, EMBASE 
and Cochrane databases. Results: Resource use associated with SHE, as a function 
of successful administration of glucagon, has not been systematically evaluated in the 
literature. Uncertainty exists for the probability of receiving a glucagon prescription 
for diabetics and successful use of glucagon kits. Furthermore, based on success-
ful administration of glucagon, the probability of ambulance calls, transports to the 
ED, inpatient admissions, and frequency of outpatient follow-up are lacking in the 
literature. ConClusions: Diabetes is a costly condition for payers, and a common 
complication is hypoglycemia. Glucagon kits are effective in stabilizing diabetics’ 
blood glucose levels during SHE; however, oftentimes physicians do not prescribe, 
patients do not fill, or caregivers do not successfully administer glucagon due to 
the complex administration procedures. As less complicated glucagon products are 
developed, their value propositions must be informed by the economic implications 
resulting from the complex administration requirements of current kits. However, the 
current literature does not systematically evaluate these implications. Consequently, 
future research is needed to quantify the impact of non-successful administration of 
glucagon rescue kits, as well as the extent of under-utilization.
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objeCtives: HIPOS-ER is an observational, cross-sectional, multicenter national 
study to describe the patient population of type 2 diabetics with hypoglycemic epi-
sodes that enter the emergency department caused by an anti-hyperglycemic agent 
(AHA). A key secondary objective is to estimate health care resource consumption 
and costs associated with this type of hypoglycemias. Methods: The study was con-
ducted in 7 centers in mainland Portugal for a period of 12 months (Jan2013-Jan2014). 
Patient level data and resource utilization were collected. Average costs were assessed 
by multiplying 2014 unit costs (available from public sources) with all relevant health 
care resource consumption items registered in the emergency room following the 
hypoglycemia events and through hospital accountancy for the hospitalized patients 
(length of stay x daily mean cost of hospitalization). Results: The study enrolled 238 
patients and the calculated proportion of hypoglycemic episodes among all emer-
gency events in the same period was 0.075% (95%CI: 0.067%, 0.083%). In this popula-
tion, 55.0% of the patients were using insulin, 31.5% were treated with a secretagogue, 
6.7% were on a combination of insulin and a secretagogue oral agent and 6.7% were on 
oral non-secretagogue based AHA therapy. Mean patient age was 76 years and 57.6% 
were females. Estimated mean (range) of direct costs assessed in the emergency room 
were: emergency transportation € 33 (€ 0-€ 92), drugs € 4 (€ 0-€ 45), laboratory workup 56€ 
(€ 8-€ 212), other exams € 72 (€ 0-€ 944), physician and nurse time € 30 (€ 4-€ 211) and € 14 
(€ 1-€ 90), respectively. Mean hospitalization cost was € 1,271 (€ 0-€ 26,486). Mean indirect 
cost related with productivity loss within employed patients was € 15 (€ 0-€ 1,579). Total 
cost, including direct and indirect costs, was € 1,493 (€ 34-€ 26,818) per hypoglycemic 
event. Hospitalization was the main cost driver (85% of total costs). ConClusions: 
We conclude that hypoglycemia represent a substantial cost for the Society and in 
particular for the public hospitals of the National Health System.
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passive safety pen device would result in total estimated cost savings of $17,865.40 
annually. ConClusions: The implementation of insulin pen devices in acute care 
results in cost savings, as well as time savings for nurses that may be re-directed to 
increased time at the patient bedside.
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objeCtives: The aim of this study was to assess the epidemiologic and economic 
burden of diabetic retinopathy (DR) in terms of incidence, treatment patterns 
and cost by a population-based study. Methods: Eligible patients were identi-
fied through a data warehouse (DENALI), which matches demographic, clinical 
and economic data of about 9.9 million individuals of Lombardy region. The study 
population consists of all individuals with a diagnosis of diabetes who, during the 
period 1-1-2000 to 31-12-2010 received one of the following health care services: 
hospital admission (HA) for diabetes with ophthalmic manifestations or retinal 
disorders, fluorescein angiography or angioscopy of eye, destruction of chorioretinal 
lesion, repair of retinal tear, injection of vitreous substitute, and repeated oph-
thalmic examinations. The study population was followed for a minimum of 1 to 
a maximum of 10 years. We evaluated demographic characteristics of the study 
population and costs from the National Health Service’s perspective. Results: The 
2000-2010 DR population was estimated to be around 127,000 (52% male). The aver-
age incidence per year and the 2010-prevalence were 6.1 and 24.2 per 100 diabetic 
patients. Median age (min-max) at the index event was 68.6 (0.3-104.4) with 37% 
younger than 65-years. Around 15% of the population had Charlson Comorbidity 
Index> = 1 and the overall mortality was 41.8 deaths/100 patient-years. The 10-year 
mean cost for DR patients were 17,361€ (95%C.I. 12,673-22,050) compared with 4,771€ 
in a control diabetic population without complications. HA costs represented the 
driver of total costs, ranging from 45% (index year) to 36% (last year of follow-up), fol-
lowed by drug (30-34.4%) and outpatient (25-29.7%). During the index year 13% of HA 
and outpatient costs were attributed to eye-specialist departments. Approximately 
1% received intravitreal injections in 2010. ConClusions: This study attempted 
to describe the burden of DR in Italy revealing socio-economic aspects relevant in 
terms of incidence and costs.
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objeCtives: To evaluate the economic burden and health care utilization of patients 
diagnosed with hyperpotassemia in the U.S. Medicare population. Methods: 
Hyperpotassemia patients (International Classification of Disease 9thRevision 
Clinical Modification ICD-9-CM diagnosis codes 276.7) were identified from the U.S. 
national Medicare claims from 01JAN2009 through 31DEC2011. The first diagnosis 
date was designated as the index date for the hyperpotassemia cohort. Patients 
without a hyperpotassemia diagnosis but of the same age, region, gender, index 
year and matched baseline Charlson Comorbidity Index score were identified for 
the comparison cohort, with a randomly-chosen index date to minimize selec-
tion bias. Patients were required to have continuous medical and pharmacy ben-
efits 1 year before and after the index date. Study outcomes (health care costs and 
utilizations) were compared between the disease and comparator cohorts using 
1: 1 propensity score matching (PSM). Results: A total of 90,528 patients were 
included in the hyperpotassemia and comparison cohorts. After 1: 1 PSM, 28,929 
patients were matched from each cohort, and baseline characteristics were pro-
portionate. Patients diagnosed with hyperpotassemia were more likely to utilize 
health care resources, including Medicare carrier (98.4% vs. 77.8%), Durable Medical 
Equipment (DME; 36.7% vs. 23.6%) and Home Health Agency (HHA; 18.4% vs. 7.3%) 
claims, outpatient visits (75.5% vs. 47.7%), inpatient (37.4% vs. 3.4%), skilled nursing 
facility (SNF, 13.3% vs. 3.4%) and hospice stays (1.1% vs. 0.8%) and prescription drug 
claims (54.1% vs. 50.7%). Patients diagnosed with hyperpotassemia also incurred 
higher Medicare carrier ($3,447 vs. $1,636), DME ($343 vs. $167), HHA ($938 vs. $412), 
outpatient ($11,006 vs. $4,534), inpatient ($7,156 vs. $1,463), SNF ($2,688 vs. $612), 
hospice ($244 vs. $198), pharmacy ($1,104 vs. $812) and total costs ($26,926 vs. $9,834) 
(p< 0.05). ConClusions: The economic burden and health care resource utilization 
were significantly higher for patients diagnosed with hyperpotassemia.
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objeCtives: HIPOS-ER is an observational, cross-sectional, multicenter study aimed 
(a) to describe type 2 diabetes patients treated with an anti-hyperglycemic agent 
(AHA) and admitted to the emergency room (ER) due to a hypoglycemic event and (b) 
to estimate health care resources use and its costs related with the ER hypoglycemic 
episode. In this analysis, costs within hospitalized patients following severe hypo-
glycemia assisted at the ER were specifically calculated. Methods: The study was 
conducted in 7 centers in mainland Portugal for a period of 12 months (Jan 2013 – Jan 
2014). Costs related with these hospitalized patients were calculated considering the 
hospital perspective. Unit costs for 2014 were extracted from official sources and 
reported in euros. Patient level data were used to calculate average costs. Regarding 
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p= 0.03), use of 3rd generation SU (OR= 0.86 [0.78 - 0.95]; p= 0.002), and chronic renal 
disease (OR= 1.34 [1.07 - 1.67]; p= 0.01). ConClusions: In conclusion, multiple fac-
tors, including efficacy and hypoglycemia, are associated with discontinuation of 
SU treatment after insulin initiation.
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objeCtives: Sulfonylurea (SU) may be discontinued or down-titrated due to 
hypoglycemia. Hypoglycemia may be more concerning for patients not receiving 
aggressive efficacy-driven treatment such as the dual-therapy of SU and insulin. A 
retrospective cohort study using the MarketScan database was conducted to assess 
the association between hypoglycemia and therapy changes (discontinuation or 
down-titration) among adults receiving SU therapy without insulin. Methods: 
Patients with the first SU prescription (Rx) (index date) in 2009-2011, ≥ 18 years 
of age on the index date, and with ≥ 1 year continuous enrollment pre- and post-
index were included. Patients were excluded if they received insulin within the 
1-year pre- or post-index, had ≥ 2 SUs on the index date, or had type 1, gestational 
or secondary diabetes. Therapy changes were determined during the 1-year post-
index period. Discontinuation occurred when consecutive SU fills were ≥ 90 days 
apart. Down-titration occurred when an SU fill had a lower equivalent dose than 
the index dose. Hypoglycemic events were identified using ICD-9 code between the 
index date and the therapy change or the end of the 1-year post-index period. Cox 
regression was used to evaluate the association between hypoglycemic events and 
therapy changes. Results: 97,570 patients were included in the study, of which 
50,854 (52.1%) experienced therapy changes within 1-year post-index. Patients with 
hypoglycemic events were at significantly higher risk for therapy changes (HR= 
1.86 [1.75, 1.97]; p< . 01). Specifically, they were 197% more likely to down-titrate 
(HR= 2.97 [2.53, 3.46]; p< . 01) and 80% more likely to discontinue (HR= 1.80 [1.69, 1.92]; 
p< . 01). ConClusions: Post-index hypoglycemic events are significantly associ-
ated with therapy changes among patients receiving SU without insulin, especially 
down-titration.
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objeCtives: To evaluate doctors’ adherence to Malaysian Clinical Practice 
Guideline (CPG) 2009 in the management of diabetes mellitus with co-morbidities 
in Malaysia. Methods: Cross-sectional study was done at a tertiary-care hospital 
in Malaysia. Total 51 physicians and 1020 patients’ prescriptions written by same 
physicians (20 prescriptions per physician) were analyzed. All patients had diabetes 
mellitus with co-morbidities. Depending on the recommendations of CPG 2009, 
the prescriptions were clustered as adherent and non-adherent prescriptions. All 
obtained data were analyzed using descriptive and inferential statistics. Results: A 
statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed 
between diabetes mellitus control and co-morbidities. CPG adherent had statisti-
cally weak negative association (Ф= - 0.081, p-value= 0.010) with patients having 
co-morbidities (41.6%). No statistically significant association was observed between 
CPG adherence and any other co-morbidity. Majority of the patients received guide-
lines-compliant pharmacotherapy. The overall good level of physician adherence 
with CPG 2009 was observed in the management of diabetes mellitus with co-
morbidities. ConClusions: The study explored several features of prescription 
pattern of the physicians involved in the management of diabetes mellitus with 
co-morbidities and recognized the need for improvement in their prescription pat-
tern for treating the diabetes mellitus.
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objeCtives: Diabetes is associated with a number of microvascular and macrovas-
cular complications. Diabetic macular edema (DME) is one of these complications 
and is among the leading causes of vision impairment. However, little data exists 
as to the patient-related burden of DME in Europe and the aim of the current study 
was to address this gap. Methods: Data from the 2013 5EU (France, Germany, Italy, 
Spain, and UK) National Health and Wellness Survey (NHWS) were used (N= 62,000). 
The NHWS is a patient-reported survey administered to a demographically rep-
resentative sample of adults (with respect to age, sex, and region). Patients who 
reported experiencing DME were compared with a propensity-scored matched con-
trol group of patients with diabetes but without DME. Matching variables included 
demographics, comorbidities (Charlson comorbidity index [CCI]), and diabetes 
history. Post-match, patients with DME and matched controls were compared on 
health outcomes (SF-36v2, Work Productivity and Activity Impairment, and self-
reported health care resource utilization) using general linear models. Results: 
4,088 patients reported diabetes (6.6%). Of these, 296 (7.2%) reported having DME. 
Patients with DME were more likely to have type 1 diabetes (26.4% vs. 8.5%), had been 
diagnosed with diabetes for longer (54.4% vs. 20.7% were diagnosed 16+ years), were 
more likely to use insulin (68.6% vs. 27.3%), and had a greater comorbidity burden 
(CCI = 2.2 vs. 1.6) (all p< .05), among other differences. After matching on these 
variables, patients with DME (n= 286) reported significantly worse physical health 
status (PCS: 41.1 vs. 43.2), greater overall work impairment (36.2% vs. 25.64%), and 
objeCtives: HIPOS-ER is the first national Hypoglycemia study in Portugal col-
lecting specific resource data directly in the hospitals. Here we aim to describe 
the average cost of severe hypoglycemic event by anti-hyperglycemic agent (AHA) 
class. Methods: The study was conducted in 7 centers in mainland Portugal for 
a period of 12 months (Jan13-Jan14). Patient level data and resource utilization 
were collected. Unit costs for 2014 were extracted from official sources. Regarding 
emergency room (ER) attendance, costs were calculated multiplying resource use by 
corresponding unit costs. For hospitalization, length of stay was multiplied by daily 
cost obtained through hospital account record. AHA therapy classes were: Group 1 
(insulin), Group 2 (secretagogue), Group 3 (oral AHA excluding secretagogue), and 
Group 4 (at least one insulin and one secretagogue). Results: 238 patients were 
enrolled and 105 (44%) were hospitalized. The distribution based on AHA therapy: 
55% (131) Group 1, 32% (75) Group 2, 7% (16) Group 3 and 7% (16) Group 4. After ER 
episode, Group 2 patients were more often hospitalized versus Group 1 (71% vs. 29%; 
p< 0.001) and Group 4 (31%; p= 0.003). The global cost was 1,493€ (34€ -26,818€ ) and 
hospitalization was the main cost driver accounting for 85% of costs. The total cost 
per AHA class was: Group 1: 1,309€ ; Group 2: 1,880€ ; Group 3: 1,350€ ; Group 4: 1,330€ . 
When comparing ER-only vs. hospitalized: Group 1: 167€ vs. 4,105€ ; Group 2: 185€ 
vs. 2,583€ ; Group 3: 156€ vs. 2,278€ ; Group 4: 237€ vs. 3,734€ . Group 1 accounted for 
48% of overall costs, Group 2 40%, Groups 3 and 4, 6% each. Group 2 had the highest 
hospitalization rate (70.7%). ConClusions: AHA classes may contribute differently 
for costs associated with severe hypoglycemia. Insulin based therapy had the great-
est overall cost followed closely by secretagogue type drugs, which were associated 
with more hospitalizations.
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objeCtives: The aim of this study was to assess the burden of severe hypogly-
cemia (HYPO) and diabetes ketoacidosis (DKA) in terms of incidence, treatment 
patterns and cost in Italy. Methods: Eligible patients were identified through a 
data warehouse (DENALI), which matches with a probabilistic linkage demographic, 
clinical and economic data of about 9.9 million individuals of Lombardy region. The 
study population was made of all individuals with a diagnosis of type-1 diabetes 
(T1DM) who, during the period 1-1-2000 to 31-12-2010 developed a first episode of 
severe HYPO (ICD-9-CM: 251.0-251.2) or DKA (ICD-9-CM: 250.10-250.13) leading to 
hospitalization (index event). The identified individuals were followed-up from the 
index event to a maximum of 10 years. We evaluated demographic characteristics 
of the study population and costs (hospitalizations, drugs and outpatient exami-
nations/visits) from the National Health Service’s perspective. Results: During 
the observational period 1,321 T1DM subjects had at least one hospital admission 
for HYPO (27.5%) or DKA (72.5%) event. Median age (min-max) at the first HYPO 
or DKA event was 66.9 (1.3-96.7) and 39.4 (1.0-95.7) years, respectively. The overall 
mortality was 14.3 deaths/100 patient-years among HYPO subjects and 7.0 among 
DKA ones: the difference in mortality rates between groups disappeared once 
controlling for age. The mean costs with 95% C.I. (€ /patient-year) for HYPO and 
DKA patients were, respectively 10,442 (8,755-12,129) and 9,720 (8,659-10,782) in 
the event year, 10,296 (8,446-12,145) and 5,805 (4,539-7,071) in the year before the 
event, and 5,619 (3,841-7,398) and 4,974 (3,912-6,035) in the year after the event. 
Hospitalizations represented the driver of total costs: in the year of event and in the 
year after it varied from 70 to 56% and 76 to 60% for HYPO and DKA patients, respec-
tively. ConClusions: This study attempted to address the burden of severe T1DM 
HYPO and DKA events in Italy in an unselected population. The burden showed to 
be relevant in terms of incidence, mortality and costs.
DiaBeTeS/enDocrine DiSorDerS – Patient-reported outcomes & Patient 
Preference Studies
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objeCtives: Sulfonylureas (SU) represent a common treatment for type 2 diabetes 
(T2DM), but they are associated with hypoglycemia, weight gain, and possibly car-
diovascular events. The purpose of this study is to evaluate factors associated with 
SU discontinuation after insulin initiation. Methods: Patients ≥ 21 years old with 
a T2DM diagnosis between 2005 and 2012 were identified using the GE electronic 
medical records database. Index date was defined as the first insulin prescription 
(Rx) between 2006 and 2011. Patients were required to be on SU at the index date. 
Patients were excluded if they did not have medical records available ≥ 12 months 
before and after index date, were receiving insulin in the 12 months prior to index 
date, or had other forms of diabetes. Treatment with other diabetes medications in 
addition to SU and insulin were permitted in this study. SU discontinuation occurred 
when the gap between the end date of current SU Rx supply and the start date of 
subsequent SU supply was ≥ 90 days apart. Multivariate logistic regression was 
performed to identify factors associated with SU discontinuation. Results: A total 
of 8,185 patients were selected, with mean age 64 years and 49% were male. 60.4% 
discontinued their SU Rxs within 1 year, with a median time from insulin initia-
tion to SU discontinuation of 88 days. In the logistic regression, baseline diagnosed 
hypoglycemia (OR= 2.29 [95% CI 1.03 - 5.10]; p= 0.04) and baseline HbA1c (OR= 1.04 
[1.01 - 1.06]; p= 0.004) were identified as factors associated with SU discontinuation. 
Additional factors included BMI (< 25 kg/m2 vs. ≥ 30 kg/m2; OR= 1.23 [1.03 - 1.46]; 
